At the time of the presentation, a live webcast of OncoSec’s presentation will be available at the following link: http://www.veracast.com/webcasts/bio/ceoinvestor2014/93140467248.cfm.
OncoSec recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. Participants will require Windows Media Player (a free download from the presentation link) in order to participate. After the presentation, an archived version of the webcast will be available on OncoSec’s web page at http://www.oncosec.com under the “Events” tab.
About the BIO CEO & Investor Conference
The BIO CEO & Investor Conference, now in its 16th year, is the largest independent investor conference focused on leading publicly traded biotechnology companies. This year’s conference will feature corporate presentations from more than 150 leading biotechnology and pharmaceutical companies, five Fireside Chats with industry leaders, three Therapeutic Workshops and three Business Roundtables all drawing from seasoned industry executives and analysts. The conference is designed to foster an informative dialogue between institutional investors and senior biotechnology executives about emerging and current investment opportunities. To find out more information on the event, visit http://www.bio.org/events/conferences/bio-ceo-investor-conference.
OncoSec's clinical programs currently include three Phase 2 clinical trials targeting metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma. As the company continues to evaluate ImmunoPulse as monotherapy in these indications, it is also investigating additional indications as well as efficacious combination approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the
Most Popular Stories
- BofA CEO Gets a 77 Percent Pay Bump
- Russia, Crimea Discuss Referendum
- Rand Paul Tells Rivals to Peddle Their Own Ideas
- Boeing Shares Fall on New Dreamliner Delay
- Goya Nutritionist Answers Demand for Healthy Hispanic Dishes
- Ukraine Crisis Sets U.S. Stocks Adrift
- Ukraine Says Russia Can't Have Crimea
- Gazprom Warns Ukraine to Pay Its Gas Bill
- FBI Investigating For-Profit Prison Company
- Alan Mulally Gets Big Payday From Ford